HIV Vaccine Efficacy Trials and Community Participation

HIV vaccine efficacy trials have advanced through successive phases, aiming to identify immunogens capable of eliciting broadly neutralising antibodies and durable cellular immunity. Early-phase trials focus on safety and immunogenicity, while later phase III evaluations assess protective efficacy in diverse populations. Despite the modest efficacy observed in some studies, progress has been underpinned by iterative design, adjuvant development and the incorporation of novel vectors. Integral to trial success is community participation, which encompasses engagement, recruitment, informed consent and retention. Altruism, trust in researchers, perceived personal and social benefits, and access to healthcare services characterise participant motivations across demographics—ranging from key populations at heightened risk to general cohorts. Conversely, barriers such as vaccine-induced seropositivity, logistical constraints, mistrust of institutions and stigma can undermine enrolment and adherence. Embedding social-behavioural research and community advisory mechanisms has proven essential in tailoring protocols, refining communication strategies and fostering mutual accountability. Through global collaboration and local empowerment, these trials not only generate robust efficacy data but also strengthen health systems, build scientific capacity and help chart the path to a world free of HIV.

Research from Nature Portfolio

No recent Nature Portfolio content available.

HIV Vaccine Efficacy Trials and Community Participation publication trend

The graph below shows the total number of articles in hiv vaccine efficacy trials and community participation across all publications each year (not limited to Nature Index journals).

Technical terms

Vaccine-induced seropositivity: A false-positive result on standard HIV antibody tests resulting from vaccination rather than infection.

Phase I/II trials: Early clinical studies assessing the safety, tolerability and immunogenicity of candidate vaccines in small cohorts.

Socio-behavioural research: Studies that investigate the social, cultural and behavioural factors influencing participant experiences and trial outcomes.

Community advisory board: A group of lay members and stakeholders who provide guidance on trial design, ethics and participant engagement.

Key populations: Groups at elevated risk of HIV infection, including people who inject drugs, men who have sex with men and sex workers.

References

1. How Biomedical HIV Prevention Trials Incorporate Behavioral and Social Sciences Research: A Typology of Approaches. AIDS and Behavior (2018).
2. Acceptability of a hypothetical preventative HIV vaccine among people who use drugs in Vancouver, Canada. BMC Public Health (2020).
3. Willingness to participate in future HIV vaccine trials among men who have sex with men and female sex workers living in Nairobi, Kenya. PLOS ONE (2020).